공시 • Apr 18
BetterLife Pharma Inc. announced that it has received CAD 0.4996 million in funding On April 17, 2026, BetterLife Pharma Inc. closed the transaction. Dr. Ahmad Doroudian, chief executive officer of the company, subscribed for a total of 1,250,000 units under the offering. 공시 • Apr 09
BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding BetterLife Pharma Inc announced non-brokered private placement offering to issue 7,142,857 unit at an issue price of CAD 0.07 for the proceeds of CAD 499,999.99 on April 8, 2026. Each unit consisting of one common share in the capital of the company and one full common share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 for up to two years following the date of the closing of the private placement. The offering is expected to close on or about April 17, 2026, and is subject to execution of agreements by the placees and to certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws. 공시 • May 28
Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001 BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. Thisphenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. Only BETR-001 treatment was able to significantly induce formation of new spines (green stain) in cultured neurons. Based on its excellent neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for first first half of 2026. 공시 • May 19
BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025 BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025. 공시 • May 15
BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/an anxiety animal models. Current methods of treating depression/an anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/an anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5 HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BETR-001 for treatment the treatment of various psychiatric and neurological diseases. 공시 • Mar 31
BetterLife Pharma Inc. Appoints Steven Sangha to its Board of Directors BetterLife Pharma Inc. announced it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia. 